Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1311-1320

  Saito, Teruyoshi ^a   Kawana, Hidetada ^b   Azuma, Kazuhiko ^a   Toyoda, Akihiro ^a   Fujita, Hiroshi ^c   Kitagawa, Motoo ^a   Harigaya, Kenichi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c SEIKAGAKU CORPORATION   (Japan)

Author keywords

CD44; Chemokinesis; Hyaluronan; Hyaluronan synthase 2; Hyaluronidase 2

Indexed keywords

AUTOCRINE MOTILITY FACTOR; COMPLEMENTARY DNA; HERMES ANTIGEN; HIGH MOLECULAR WEIGHT HYALURONAN; HYALURONIC ACID; HYALURONIDASE; LOW MOLECULAR WEIGHT HYALURONAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARBOHYDRATE METABOLISM; CELL MEMBRANE; CHEMOKINESIS; ENZYME DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPRESSION VECTOR; GENE SILENCING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, CD44; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; GLUCURONOSYLTRANSFERASE; GPI-LINKED PROTEINS; HELA CELLS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MOLECULAR WEIGHT;

EID: 80053207343     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1114     Document Type: Article

References (80)

1. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539, 2004.
2. McBride WH and Bard JB: Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 149: 507-515, 1979. (Pubitemid 9122868)
3. Feinberg RN and Beebe DC: Hyaluronate in vasculogenesis. Science 220: 1177-1179, 1983. (Pubitemid 13097206)
4. Delmage JM, Powars DR, Jaynes PK and Allerton SE: The selective suppression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci 16: 303-310, 1986. (Pubitemid 16099602)
5. Lokeshwar VB, Obek C, Soloway MS and Block NL: Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 57: 773-777, 1997. (Pubitemid 27085665)
6. Lokeshwar VB, Rubinowicz D, Schroeder GL, et al: Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276: 11922-11932, 2001.
7. Turley EA, Noble PW and Bourguignon LY: Signaling properties of hyaluronan receptors. J Biol Chem 277: 4589-4592, 2002. (Pubitemid 34968484)
8. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L and Hung MC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272: 27913-27918, 1997. (Pubitemid 27473595)
9. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF and Raj MH: In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol 171: 2033-2039, 2007.
10. Fujita Y, Kitagawa M, Nakamura S, et al: CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett 528: 101-108, 2002. (Pubitemid 35258007)
11. Naor D, Nedvetzki S, Golan I, Melnik L and Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci 39: 527-579, 2002. (Pubitemid 35425379)
12. Lokeshwar VB and Selzer MG: Hyalurondiase: both a tumor promoter and suppressor. Semin Cancer Biol 18: 281-287, 2008.
13. Toole BP: Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 15: 7462-7468, 2009.
14. Itano N, Sawai T, Yoshida M, et al: Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 274: 25085-25092, 1999.
15. Weigel PH, Hascall VC and Tammi M: Hyaluronan synthases. J Biol Chem 272: 13997-14000, 1997. (Pubitemid 27232793)
16. Bharadwaj AG, Rector K and Simpson MA: Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J Biol Chem 282: 20561-20572, 2007. (Pubitemid 47100011)
17. Li Y, Li L, Brown TJ and Heldin P: Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 120: 2557-2567, 2007. (Pubitemid 46651275)
18. Itano N and Kimata K: Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol 18: 268-274, 2008.
19. Golshani R, Lopez L, Estrella V, Kramer M, Iida N and Lokeshwar VB: Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68: 483-491, 2008. (Pubitemid 351380075)
20. Itano N, Sawai T, Atsumi F, et al: Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 279: 18679-18687, 2004. (Pubitemid 38623291)
21. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG and Simpson MA: Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 174: 1027-1036, 2009.
22. Simpson MA, Wilson CM and McCarthy JB: Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 161: 849-857, 2002. (Pubitemid 34988372)
23. Udabage L, Brownlee GR, Waltham M, et al: Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 65: 6139-6150, 2005. (Pubitemid 40994399)
24. Kosaki R, Watanabe K and Yamaguchi Y: Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 59: 1141-1145, 1999. (Pubitemid 29135978)
25. Nishida Y, Knudson W, Knudson CB and Ishiguro N: Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 307: 194-203, 2005. (Pubitemid 40732745)
26. Camenisch TD, Schroeder JA, Bradley J, Klewer SE and McDonald JA: Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8: 850-855, 2002.
27. Camenisch TD, Spicer AP, Brehm-Gibson T, et al: Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 106: 349-360, 2000. (Pubitemid 30655635)
28. Rodgers LS, Lalani S, Hardy KM, et al: Depolymerized hyaluronan induces vascular endothelial growth factor, a negative regulator of developmental epithelial-to-mesenchymal transformation. Circ Res 99: 583-589, 2006. (Pubitemid 44401449)
29. Zoltan-Jones A, Huang L, Ghatak S and Toole BP: Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 278: 45801-45810, 2003. (Pubitemid 37432725)
30. Jenkins RH, Thomas GJ, Williams JD and Steadman R: Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover. J Biol Chem 279: 41453-41460, 2004. (Pubitemid 39313585)
31. Csoka AB, Frost GI and Stern R: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20: 499-508, 2001. (Pubitemid 33109098)
32. Csoka AB, Scherer SW and Stern R: Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 60: 356-361, 1999. (Pubitemid 29471502)
33. Stern R: Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology 13: R105-R115, 2003.
34. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI and Miller AD: Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci USA 98: 4443-4448, 2001. (Pubitemid 32294996)
35. Lepperdinger G, Strobl B and Kreil G: HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 273: 22466-22470, 1998. (Pubitemid 28399812)
36. Harada H and Takahashi M: CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 282: 5597-5607, 2007. (Pubitemid 47093756)
37. de la Motte C, Nigro J, Vasanji A, et al: Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol 174: 2254-2264, 2009.
38. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991-27007, 2004.
39. Udabage L, Brownlee GR, Nilsson SK and Brown TJ: The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310: 205-217, 2005. (Pubitemid 41393701)
40. Hu M, Pollock RE and Nicolson GL: Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin. Cancer Res 57: 3577-3584, 1997. (Pubitemid 27355510)
41. Liotta LA, Mandler R, Murano G, et al: Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83: 3302-3306, 1986. (Pubitemid 16043024)
42. Toyoda A, Kawana H, Azuhata K, et al: Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. Int J Oncol 34: 53-60, 2009.
43. Shimabukuro Y, Ichikawa T, Takayama S, et al: Fibroblast growth factor-2 regulates the synthesis of hyaluronan by human periodontal ligament cells. J Cell Physiol 203: 557-563, 2005. (Pubitemid 40629018)
44. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989. (Pubitemid 19132276)
45. Qiang YW, Kitagawa M, Higashi M, Ishii G, Morimoto C and Harigaya K: Activation of mitogen-activated protein kinase through alpha5/beta1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol 28: 1147-1157, 2000.
46. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987. (Pubitemid 17158816)
47. Draffin JE, McFarlane S, Hill A, Johnston PG and Waugh DJ: CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64: 5702-5711, 2004. (Pubitemid 39095568)
48. Wang F, Grigorieva EV, Li J, et al: HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One 3: e3031, 2008.
49. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U and Kosma VM: High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37: 849-856, 2001. (Pubitemid 32323962)
50. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV and Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60: 150-155, 2000. (Pubitemid 30058745)
51. Auvinen P, Tammi R, Parkkinen J, et al: Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156: 529-536, 2000. (Pubitemid 30643808)
52. Pirinen R, Tammi R, Tammi M, et al: Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 95: 12-17, 2001.
53. Posey JT, Soloway MS, Ekici S, et al: Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 63: 2638-2644, 2003. (Pubitemid 36605207)
54. Fieber C, Baumann P, Vallon R, et al: Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell Sci 117: 359-367, 2004. (Pubitemid 38128913)
55. Voelcker V, Gebhardt C, Averbeck M, et al: Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 17: 100-107, 2008.
56. West DC, Hampson IN, Arnold F and Kumar S: Angiogenesis induced by degradation products of hyaluronic acid. Science 228: 1324-1326, 1985.
57. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H and Miyasaka M: Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 278: 32259-32265, 2003. (Pubitemid 37048419)
58. Duterme C, Mertens-Strijthagen J, Tammi M and Flamion B: Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. J Biol Chem 284: 33495-33508, 2009.
59. Thomas L, Byers HR, Vink J and Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 118: 971-977, 1992.
60. Herrera-Gayol A and Jothy S: Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 66: 149-156, 1999. (Pubitemid 29347503)
61. Fujii K, Tanaka Y, Hubscher S, Saito K, Ota T and Eto S: Cross-linking of CD44 on rheumatoid synovial cells up-regulates VCAM-1. J Immunol 162: 2391-2398, 1999. (Pubitemid 29288867)
62. Fujisaki T, Tanaka Y, Fujii K, et al: CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res 59: 4427-4434, 1999. (Pubitemid 29418764)
63. Noble PW, Lake FR, Henson PM and Riches DW: Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J Clin Invest 91: 2368-2377, 1993. (Pubitemid 23182485)
64. Fujii K, Tanaka Y, Hubscher S, Saito K, Ota T and Eto S: Crosslinking of CD44 on rheumatoid synovial cells augment interleukin 6 production. Lab Invest 79: 1439-1446, 1999. (Pubitemid 30013908)
65. McKee CM, Penno MB, Cowman M, et al: Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98: 2403-2413, 1996. (Pubitemid 26394217)
66. Webb DS, Shimizu Y, Van Seventer GA, Shaw S and Gerrard TL: LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 249: 1295-1297, 1990.
67. Wittig BM, Johansson B, Zoller M, Schwarzler C and Gunthert U: Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 191: 2053-2064, 2000.
68. Ayroldi E, Cannarile L, Migliorati G, Bartoli A, Nicoletti I and Riccardi C: CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 86: 2672-2678, 1995.
69. Allouche M, Charrad RS, Bettaieb A, Greenland C, Grignon C and Smadja-Joffe F: Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells. Blood 96: 1187-1190, 2000. (Pubitemid 30616894)
70. Bourguignon LY, Zhu H, Shao L and Chen YW: CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 275: 1829-1838, 2000. (Pubitemid 30060806)
71. Oliferenko S, Kaverina I, Small JV and Huber LA: Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. J Cell Biol 148: 1159-1164, 2000.
72. Cywes C and Wessels MR: Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature 414: 648-652, 2001. (Pubitemid 33151261)
73. Fitzgerald KA, Bowie AG, Skeffington BS and O'Neill LA: Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. J Immunol 164: 2053-2063, 2000. (Pubitemid 30108763)
74. Orian-Rousseau V and Ponta H: Adhesion proteins meet receptors: a common theme? Adv Cancer Res 101: 63-92, 2008.
75. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074-3086, 2002. (Pubitemid 35424194)
76. Yu WH, Woessner JF Jr, McNeish JD and Stamenkovic I: CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16: 307-323, 2002. (Pubitemid 34111411)
77. Pienimaki JP, Rilla K, Fulop C, et al: Epidermal growth factor activates hyaluronan synthase 2 in epidermal keratinocytes and increases pericellular and intracellular hyaluronan. J Biol Chem 276: 20428-20435, 2001.
78. Saavalainen K, Pasonen-Seppanen S, Dunlop TW, Tammi R, Tammi MI and Carlberg C: The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene. J Biol Chem 280: 14636-14644, 2005. (Pubitemid 40562809)
79. Godar S, Ince TA, Bell GW, et al: Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134: 62-73, 2008. (Pubitemid 351905743)
80. Wielenga VJ, Smits R, Korinek V, et al: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523, 1999. (Pubitemid 29094101)